DRUG QUANTITY MANAGEMENT POLICY – PER DAYS

POLICY: Inflammatory Conditions – Tremfya Drug Quantity Management Policy – Per Days
- Tremfya® (guselkumab subcutaneous injection – Janssen/Johnson & Johnson)

REVIEW DATE: 12/19/2022

OVERVIEW
Tremfya, an interleukin (IL)-23 blocker, is indicated for the following uses:[1]
- **Plaque psoriasis**, in adults with moderate to severe disease who are candidates for systemic therapy or phototherapy.
- **Psoriatic arthritis**, in adults with active disease (given ± a conventional synthetic disease-modifying antirheumatic drug).

Dosing
Tremfya is administered by a subcutaneous (SC) injection.[1] For both plaque psoriasis and psoriatic arthritis, the recommended dose is 100 mg SC at Week 0 and Week 4, then 100 mg SC once every 8 weeks thereafter.

Availability
Tremfya is available in the following forms:[1]
- 100 mg/mL single-dose patient-controlled injector
- 100 mg/mL single-dose prefilled syringe

POLICY STATEMENT
This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Tremfya, and to manage potential premature dose escalation. If the Drug Quantity Management rule is not met at the point of service, coverage will be determined by the Criteria below. All approvals are provided for the duration noted below.

Automation: None.

Drug Quantity Limits

Product	Strength and Form	Retail and Home Delivery Maximum Quantity per 56 Days
Tremfya® (guselkumab subcutaneous injection)	100 mg patient-controlled injector	1 injector
	100 mg/mL prefilled syringe	1 syringe

CRITERIA

1. If the patient is initiating treatment or requires additional induction dosing, as verified by the absence of claims for Tremfya in the past 130 days, approve a one-time override for 2 prefilled syringes or patient-controlled injectors at retail or home delivery.

REFERENCES
1. Tremfya® subcutaneous injection [prescribing information]. Horsham, PA: Janssen/Johnson & Johnson; July 2020.